Human Genome Sciences, Kirin antibody deal

HGSI and Kirin Brewery (Tokyo, Japan) will jointly study their respective human monoclonal antibody agonists of the TRAIL Receptor-2 protein, and take a selected lead compound into the clinic to treat cancer. Kirin will develop and commercialize any resulting drugs in Asia, Australia and New Zealand. HGSI will develop and commercialize any resulting therapeutics in the rest of the world. Kirin will pay milestone payments and royalties to HGSI for any TRAIL-R2 MAb product that is developed and marketed in its areas and HGSI will pay royalties to Kirin on sales in the rest of the world. ...